Industry-sponsored trials and incentives

Treating cancer is a massive business. In 2024 alone, cancer treatments generated at least $200 billion in worldwide sales for the pharmaceutical industry, more than the obesity drug rush. But a Bloomberg News analysis showed that fewer than half of treatments reviewed — some of which have painful side effects — have been shown to extend patients’ lives.

On today’s Big Take podcast, Bloomberg senior healthcare reporter Robert Langreth takes host David Gura inside what some doctors call the “cancer-industrial complex” — from the regulatory landscape that ushered in a wave of lucrative new drugs to the damaging financial and health impacts some treatments can have on patients.

Read more:

Cancer Drugs Cost More Than Ever. They Often Don’t Extend Lives.

The Implants Were Supposed to Dissolve. They Didn’t.

Pharma Is Pushing $200,000 Cancer Drugs When Cheaper Doses May Work

Cancer Doctors Are Making a Fortune Off Drug-Trial Participants

One Generic Cancer Drug Costs $35. Or $134. Or $13,000.

See omnystudio.com/listener for privacy information.